Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes

Seminars in Cancer Biology

Volumn 21, Issue 5, 2011, Pages 293-298

  Smedby, Karin E ^a   Hjalgrim, Henrik ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

Epidemiology; Etiology; Mantle cell lymphoma; Non Hodgkin lymphoma

Indexed keywords

IMMUNOSUPPRESSIVE AGENT;

AGE DISTRIBUTION; AUTOIMMUNE DISEASE; BORRELIA BURGDORFERI; BURKITT LYMPHOMA; CANCER INCIDENCE; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS INFECTION; FAMILY HISTORY; GENE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HELICOBACTER INFECTION; HEMATOLOGIC MALIGNANCY; HEPATITIS C; HUMAN; HUMAN HERPESVIRUS 8; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; INTERLEUKIN 10 GENE; KAPOSI SARCOMA; LIFESTYLE; LYME DISEASE; LYMPHOPLASMACYTIC LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHODGKIN LYMPHOMA; OCCUPATIONAL HAZARD; REVIEW; RISK FACTOR; SEX RATIO; SOMATIC HYPERMUTATION; TUMOR NECROSIS FACTOR GENE;

HUMANS; INCIDENCE; LYMPHOMA, MANTLE-CELL; LYMPHOMA, NON-HODGKIN; RISK FACTORS;

EID: 82555169684     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2011.09.010     Document Type: Review

References (71)

1. Rappaport H., Winter W., Hicks E. Follicular lymphoma. A re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer 1956, 9:792-821.
2. Banks P.M., Chan J., Cleary M.L., Delsol G., De Wolf-Peeters C., Gatter K., et al. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 1992, 16:637-640.
3. Harris N.L., Jaffe E.S., Stein H., Banks P.M., Chan J.K., Cleary M.L., et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361-1392.
4. Pathology and genetics of tumours of hematopoietic and lymphoid tissues 2001, IARC Press, Lyon. E.S. Jaffe, H. Stein, J.W. Vardiman (Eds.).
5. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
6. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997, 89:3909-3918.
7. Zhou Y., Wang H., Fang W., Romaguer J.E., Zhang Y., Delasalle K.B., et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008, 113:791-798.
8. Sant M., Allemani C., Tereanu C., De Angelis R., Capocaccia R., Visser O., et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010, 116:3724-3734.
9. Morton L.M., Wang S.S., Devesa S.S., Hartge P., Weisenburger D.D., Linet M.S. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107:265-276.
10. WHO classification of tumours of hematopoietic and lymphoid tissues 2008, IARC Press, Lyon. 4th edition. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein (Eds.).
11. Coleman M.P., Esteve J., Damiecki P., Arslan A., Renard H. Trends in cancer incidence and mortality 1993, [Lyon].
12. Roman E., Smith A.G. Epidemiology of lymphomas. Histopathology 2011, 58:4-14.
13. Marcos-Gragera R., Pollan M., Chirlaque M.D., Guma J., Sanchez M.J., Garau I. Attenuation of the epidemic increase in non-Hodgkin's lymphomas in Spain. Ann Oncol 2010, 21(Suppl. 3):iii90-iii96.
14. Sandin S., Hjalgrim H., Glimelius B., Rostgaard K., Pukkala E., Askling J. Incidence of non-Hodgkin's lymphoma in Sweden, Denmark, and Finland from 1960 through 2003: an epidemic that was. Cancer Epidemiol Biomarkers Prev 2006, 15:1295-1300.
15. Hartge P., Devesa S.S. Quantification of the impact of known risk factors on time trends in non-Hodgkin's lymphoma incidence. Cancer Res 1992, 52:5566s-5569s.
16. Boffetta P., Armstrong B., Linet M., Kasten C., Cozen W., Hartge P. Consortia in cancer epidemiology: lessons from InterLymph. Cancer Epidemiol Biomarkers Prev 2007, 16:197-199.
17. Ekstrom-Smedby K. Epidemiology and etiology of non-Hodgkin lymphoma - a review. Acta Oncol 2006, 45:258-271.
18. Clarke C.A., Undurraga D.M., Harasty P.J., Glaser S.L., Morton L.M., Holly E.A. Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev 2006, 15:630-638.
19. Grogg K.L., Miller R.F., Dogan A. HIV infection and lymphoma. J Clin Pathol 2007, 60:1365-1372.
20. Quinlan S.C., Pfeiffer R.M., Morton L.M., Engels E.A. Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 2011, 86:206-209.
21. Royer B., Cazals-Hatem D., Sibilia J., Agbalika F., Cayuela J.M., Soussi T., et al. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 1997, 90:766-775.
22. Theander E., Vasaitis L., Baecklund E., Nordmark G., Warfvinge G., Liedholm R., et al. Lymphoid organisation in labial salivary gland biopsies is a possible predictor for the development of malignant lymphoma in primary Sjogren's syndrome. Ann Rheum Dis 2011, 70:1363-1368.
23. Wotherspoon A.C., Ortiz-Hidalgo C., Falzon M.R., Isaacson P.G. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991, 338:1175-1176.
24. Lin W.C., Tsai H.F., Kuo S.H., Wu M.S., Lin C.W., Hsu P.I., et al. Translocation of Helicobacter pylori CagA into Human B lymphocytes, the origin of mucosa-associated lymphoid tissue lymphoma. Cancer Res 2010, 70:5740-5748.
25. van Leeuwen M.T., Grulich A.E., Webster A.C., McCredie M.R., Stewart J.H., McDonald S.P., et al. Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood 2009, 114:630-637.
26. van Leeuwen M.T., Vajdic C.M., Middleton M.G., McDonald A.M., Law M., Kaldor J.M., et al. Continuing declines in some but not all HIV-associated cancers in Australia after widespread use of antiretroviral therapy. AIDS 2009, 23:2183-2190.
27. Epeldegui M., Vendrame E., Martinez-Maza O. HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma. Immunol Res 2010, 48:72-83.
28. Fernberg P, Edgren G, Adami J, Ingvar A, Bellocco R, Tufveson G, et al. Time trends in risk and risk determinants of non-Hodgkin lymphoma in solid organ transplant recipients. Am J Transplant; 2011 Aug 22 [Epub ahead of print].
29. Jarrett R.F. Viruses and lymphoma/leukaemia. J Pathol 2006, 208:176-186.
30. Giordano T.P., Henderson L., Landgren O., Chiao E.Y., Kramer J.R., El-Serag H., et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007, 297:2010-2017.
31. Engels E.A., Cho E.R., Jee S.H. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol 2010, 11:827-834.
32. de Sanjose S., Benavente Y., Vajdic C.M., Engels E.A., Morton L.M., Bracci P.M., et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008, 6:451-458.
33. Ferreri A.J., Dolcetti R., Magnino S., Doglioni C., Ponzoni M. Chlamydial infection: the link with ocular adnexal lymphomas. Nat Rev Clin Oncol 2009, 6:658-669.
34. Peterson M.C. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004, 350:1685-1686. [author reply 1686].
35. Garbe C., Stein H., Dienemann D., Orfanos C.E. Borrelia burgdorferi-associated cutaneous B cell lymphoma: clinical and immunohistologic characterization of four cases. J Am Acad Dermatol 1991, 24:584-590.
36. Munksgaard L., Obitz E.R., Goodlad J.R., Davidson M.M., Ho-Yen D.O., Hamilton-Dutoit S., et al. Demonstration of B. burgdorferi-DNA in two cases of nodal lymphoma. Leuk Lymphoma 2004, 45:1721-1723.
37. Schöllkopf C., Melbye M., Munksgaard L., Smedby K.E., Rostgaard K., Glimelius B., et al. Borrelia infection and risk of non-Hodgkin lymphoma. Blood 2008, 111:5524-5529.
38. Aberer E., Fingerle V., Wutte N., Fink-Puches R., Cerroni L. Within European margins. Lancet 2011, 377:178.
39. Thelander E.F., Rosenquist R. Molecular genetic characterization reveals new subsets of mantle cell lymphoma. Leuk Lymphoma 2008, 49:1042-1049.
40. Garcia-Munoz R., Panizo C., Bendandi M., Llorente L. Autoimmunity and lymphoma: is mantle cell lymphoma a mistake of the receptor editing mechanism?. Leuk Res 2009, 33:1437-1439.
41. Schraders M., Oeschger S., Kluin P.M., Hebeda K., Schuuring E., Groenen P.J., et al. Hypermutation in mantle cell lymphoma does not indicate a clinical or biological subentity. Mod Pathol 2009, 22:416-425.
42. Hadzidimitriou A., Agathangelidis A., Darzentas N., Murray F., Delfau-Larue M.H., Bredo Pedersen L., et al. Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood 2011, 118:2088-2095.
43. Romaguera J.E., Medeiros L.J., Hagemeister F.B., Fayad L.E., Rodriguez M.A., Pro B., et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003, 97:586-591.
44. Rule S.A., Poplar S., Evans P.A., O'Connor S.J., Owen R.G. Indolent mantle-cell lymphoma: immunoglobulin variable region heavy chain sequence analysis reveals evidence of disease 10 years prior to symptomatic clinical presentation. J Clin Oncol 2011, 29:e437-e439.
45. Smedby K.E., Askling J., Mariette X., Baecklund E. Autoimmune and inflammatory disorders and risk of malignant lymphomas - an update. J Intern Med 2008, 264:514-527.
46. Smedby K.E., Hjalgrim H., Askling J., Chang E.T., Gregersen H., Porwit-MacDonald A., et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 2006, 98:51-60.
47. Ekstrom Smedby K., Vajdic C.M., Falster M., Engels E.A., Martinez-Maza O., Turner J., et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 2008, 111:4029-4038.
48. Willett E.V., Morton L.M., Hartge P., Becker N., Bernstein L., Boffetta P., et al. Non-Hodgkin lymphoma and obesity: a pooled analysis from the InterLymph Consortium. Int J Cancer 2008, 122:2062-2070.
49. Morton L.M., Zheng T., Holford T.R., Holly E.A., Chiu B.C., Costantini A.S., et al. Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis. Lancet Oncol 2005, 6:469-476.
50. Morton L.M., Hartge P., Holford T.R., Holly E.A., Chiu B.C., Vineis P., et al. Cigarette smoking and risk of non-Hodgkin lymphoma: a pooled analysis from the International Lymphoma Epidemiology Consortium (interlymph). Cancer Epidemiol Biomarkers Prev 2005, 14:925-933.
51. Kricker A., Armstrong B.K., Hughes A.M., Goumas C., Smedby K.E., Zheng T., et al. Personal sun exposure and risk of non Hodgkin lymphoma: a pooled analysis from the Interlymph Consortium. Int J Cancer 2008, 122:144-154.
52. Vajdic C.M., Falster M.O., de Sanjose S., Martinez-Maza O., Becker N., Bracci P.M., et al. Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. Cancer Res 2009, 69:6482-6489.
53. Clapp R.W., Jacobs M.M., Loechler E.L. Environmental and occupational causes of cancer: new evidence 2005-2007. Rev Environ Health 2008, 23:1-37.
54. Eriksson M., Hardell L., Carlberg M., Akerman M. Pesticide exposure as risk factor for non-Hodgkin lymphoma including histopathological subgroup analysis. Int J Cancer 2008, 123:1657-1663.
55. Cocco P., t'Mannetje A., Fadda D., Melis M., Becker N., de Sanjose S., et al. Occupational exposure to solvents and risk of lymphoma subtypes: results from the Epilymph case-control study. Occup Environ Med 2010, 67:341-347.
56. Kane E.V., Newton R. Occupational exposure to gasoline and the risk of non-Hodgkin lymphoma: a review and meta-analysis of the literature. Cancer Epidemiol 2010, 34:516-522.
57. Wang S.S., Slager S.L., Brennan P., Holly E.A., de Sanjose S., Bernstein L., et al. Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10211 cases and 11905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007, 109:3479-3488.
58. Chang E.T., Smedby K.E., Hjalgrim H., Porwit-MacDonald A., Roos G., Glimelius B., et al. Family history of hematopoietic malignancy and risk of lymphoma. J Natl Cancer Inst 2005, 97:1466-1474.
59. Goldin L.R., Pfeiffer R.M., Li X., Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood 2004, 104:1850-1854.
60. Chang E.T., Smedby K.E., Hjalgrim H., Glimelius B., Adami H.O. Reliability of self-reported family history of cancer in a large case-control study of lymphoma. J Natl Cancer Inst 2006, 98:61-68.
61. Conde L., Halperin E., Akers N.K., Brown K.M., Smedby K.E., Rothman N., et al. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet 2010, 42:661-664.
62. Houlston R.S. Low-penetrance susceptibility to hematological malignancy. Curr Opin Genet Dev 2010, 20:245-250.
63. Rothman N., Skibola C.F., Wang S.S., Morgan G., Lan Q., Smith M.T., et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 2006, 7:27-38.
64. Fernberg P., Chang E.T., Duvefelt K., Hjalgrim H., Eloranta S., Sorensen K.M., et al. Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma. Cancer Causes Control 2010, 21:759-769.
65. Skibola C.F., Bracci P.M., Nieters A., Brooks-Wilson A., de Sanjose S., Hughes A.M., et al. Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. Am J Epidemiol 2010, 171:267-276.
66. Elahi M.M., Asotra K., Matata B.M., Mastana S.S. Tumor necrosis factor alpha-308 gene locus promoter polymorphism: an analysis of association with health and disease. Biochim Biophys Acta 2009, 1792:163-172.
67. Gibson A.W., Edberg J.C., Wu J., Westendorp R.G., Huizinga T.W., Kimberly R.P. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 2001, 166:3915-3922.
68. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009, 9:361-371.
69. Slager S.L., Rabe K.G., Achenbach S.J., Vachon C.M., Goldin L.R., Strom S.S., et al. Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood 2011, 117:1911-1916.
70. Crowther-Swanepoel D., Broderick P., Di Bernardo M.C., Dobbins S.E., Torres M., Mansouri M., et al. Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nat Genet 2010, 42:132-136.
71. Smedby K.E., Foo J.N., Skibola C.F., Darabi H., Conde L., Hjalgrim H., et al. GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet 2011, 7:e1001378.